Correlation Between ArriVent BioPharma, and Puma Biotechnology
Can any of the company-specific risk be diversified away by investing in both ArriVent BioPharma, and Puma Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ArriVent BioPharma, and Puma Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between ArriVent BioPharma, Common and Puma Biotechnology, you can compare the effects of market volatilities on ArriVent BioPharma, and Puma Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ArriVent BioPharma, with a short position of Puma Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of ArriVent BioPharma, and Puma Biotechnology.
Diversification Opportunities for ArriVent BioPharma, and Puma Biotechnology
0.71 | Correlation Coefficient |
Poor diversification
The 3 months correlation between ArriVent and Puma is 0.71. Overlapping area represents the amount of risk that can be diversified away by holding ArriVent BioPharma, Common and Puma Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Puma Biotechnology and ArriVent BioPharma, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ArriVent BioPharma, Common are associated (or correlated) with Puma Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Puma Biotechnology has no effect on the direction of ArriVent BioPharma, i.e., ArriVent BioPharma, and Puma Biotechnology go up and down completely randomly.
Pair Corralation between ArriVent BioPharma, and Puma Biotechnology
Given the investment horizon of 90 days ArriVent BioPharma, Common is expected to generate 0.71 times more return on investment than Puma Biotechnology. However, ArriVent BioPharma, Common is 1.4 times less risky than Puma Biotechnology. It trades about 0.07 of its potential returns per unit of risk. Puma Biotechnology is currently generating about 0.0 per unit of risk. If you would invest 1,800 in ArriVent BioPharma, Common on September 14, 2024 and sell it today you would earn a total of 872.00 from holding ArriVent BioPharma, Common or generate 48.44% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 83.64% |
| Values | Daily Returns |
ArriVent BioPharma, Common vs. Puma Biotechnology
Performance |
| Timeline |
| ArriVent BioPharma, |
| Puma Biotechnology |
ArriVent BioPharma, and Puma Biotechnology Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with ArriVent BioPharma, and Puma Biotechnology
The main advantage of trading using opposite ArriVent BioPharma, and Puma Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ArriVent BioPharma, position performs unexpectedly, Puma Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Puma Biotechnology will offset losses from the drop in Puma Biotechnology's long position.| ArriVent BioPharma, vs. Puma Biotechnology | ArriVent BioPharma, vs. Iovance Biotherapeutics | ArriVent BioPharma, vs. Day One Biopharmaceuticals | ArriVent BioPharma, vs. Inozyme Pharma |
| Puma Biotechnology vs. Ultragenyx | Puma Biotechnology vs. Crinetics Pharmaceuticals | Puma Biotechnology vs. Arvinas | Puma Biotechnology vs. Revolution Medicines |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Complementary Tools
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |